KMDA vs DBVT vs ADMA vs PRGO vs GRFS

For growth investors, Kamada Ltd.

(KMDA) is the stronger pick with 21. 4% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Grifols, S. A. (GRFS) offers the better valuation at 12. 0x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate Kamada Ltd. (KMDA) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grifols, S.

A. (GRFS) is the cheapest at 12. 0x versus Kamada Ltd. at 22. 3x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +386. 8%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: KMDA returned +131. 4% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Grifols, S.

A. (GRFS) is the lower-risk stock at 1. 10β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 15% more volatile than GRFS relative to the S&P 500. On balance sheet safety, Kamada Ltd. (KMDA) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Kamada Ltd.

(KMDA) is pulling ahead at 21. 4% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ADMA leads at 57. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 16. 9x for Kamada Ltd. — 11. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.

In this comparison, PRGO (9.

8% yield), GRFS (2. 6% yield), KMDA (2. 6% yield) pay a dividend. DBVT, ADMA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Kamada Ltd.

(KMDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), 2. 6% yield, +131. 4% 10Y return). Both have compounded well over 10 years (KMDA: +131. 4%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KMDA is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ADMA is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; GRFS is a small-cap deep-value stock. KMDA, PRGO, GRFS pay a dividend while DBVT, ADMA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.